Financial updates
Pharming Group reports first quarter 2024 financial results and provides business update
Pharming Group N.V. presents its preliminary (unaudited) financial report for the three months ended March 31, 2024.
- First quarter 2024 revenues increased by 31% to US$55.6 million, compared to the first quarter 2023, driven by the U.S. commercial launch of Joenja® and revenue growth of RUCONEST®
- RUCONEST® revenues increased by 8% to US$46.0 million, compared to the first quarter 2023
- Joenja® (leniolisib) revenue of US$9.6 million, a 21% increase compared to the fourth quarter of 2023
- On track for 2024 total revenue guidance of US$280 million - US$295 million (14 - 20% growth)
- Overall cash and marketable securities of US$203.5 million at the end of the quarter
- Pharming to host a conference call today at 13:30 CEST (7:30 am EDT) (view live webcast and conference call dial-in details)
Read more below